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Vancomycin-Resistant Enterococcus
faecium (VRE)
In addition to being a member of the normal
gut flora of nearly all warm-blooded animals
(including humans), E. faecium has the ability to
cause a wide range of infections, primarily
serious infections in hospital patients (particu-
larly in intensive care units). Increasing
incidence of E. faecium infections has been
associated with use of third-generation cepha-
losporins in hospitals (1). Enterococci are
resistant to many antibiotics. In an increasing
number of cases, vancomycin is the only
treatment drug that remains effective. Because
E. faecium was untreatable with practically all
other antibiotics, the emergence of the first high
level vancomycin-resistant E. faecium was of
particular concern (2). By 1997, more than 15%
of nosocomial enterococcal infections in U.S.
hospitals were due to VRE (3).
The vancomycin-resistant strain of E. faecium
(VRE) contains the VanA gene cluster located at
a mobile genetic element, a transposon
designated Tn1546. Although other mechanisms
and determinants of glycopeptide resistance
have been found in E. faecium, in this article,
VRE will refer to strains containing the vanA
gene and Tn1546. First isolated in France in
1986, VRE were subsequently found in the
United States in 1989, where they rapidly
became a frequent cause of hospital infections
(3). Like many other nosocomial pathogens, VRE
were believed to originate and be maintained in
hospitals and to have little, if any, association
with the community. Nosocomial outbreaks and
clonal spread in the United States supported this
assumption (4). In Europe, however, even
though serious incidents have occurred in some
countries, VRE-associated hospital infections
have not increased at the same rate and to the
same proportion as in the United States (5). The
first indication that the epidemiology of VRE
may differ from that of other gram-positive
organisms capable of causing hospital infections
(e.g., methicillin-resistant Staphylococcus aureus)
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Supplementing animal feed with antimicrobial agents to enhance growth has been
common practice for more than 30 years and is estimated to constitute more than half
the total antimicrobial use worldwide. The potential public health consequences of this
use have been debated; however, until recently, clear evidence of a health risk was not
available. Accumulating evidence now indicates that the use of the glycopeptide
avoparcin as a growth promoter has created in food animals a major reservoir of
Enterococcus faecium, which contains the high level glycopeptide resistance
determinant  vanA, located on the Tn1546 transposon. Furthermore, glycopeptide-
resistant strains, as well as resistance determinants, can be transmitted from animals to
humans. Two antimicrobial classes expected to provide the future therapeutic options
for treatment of infections with vancomycin-resistant enterococci have analogues
among the growth promoters, and a huge animal reservoir of resistant E. faecium has
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came from the United Kingdom, where Bates et
al. (6) reported isolating VRE from pig herds as
well as from the farm environment. These
scientists suggested that a community source of
VRE may exist. Soon afterwards, Klare et al. (7)
in Germany showed that VRE could be cultured
frequently from pigs, poultry, and humans in the
community and suggested that VRE may be
associated with the use of glycopeptides as
growth promoters in food animals.
Antimicrobial Growth Promoters
Antimicrobial growth promoters (AGPs) are
antibiotics added to the feed of food animals to
enhance their growth rate and production
performance. The mechanism by which AGPs
work is not clear. AGPs reduce normal intestinal
flora (which compete with the host for nutrients)
and harmful gut bacteria (which may reduce
performance by causing subclinical disease). The
effect on growth may be due to a combination of
both fewer normal intestinal flora and fewer
harmful bacteria. The class of antimicrobial
drugs used and the animal species involved may
determine the relative importance of each
mechanism (8). The quantity used in feed varies
with each antimicrobial agent. In the European
Union (EU), avoparcin 20 mg/kg and 40 mg/kg
was approved for different age groups of pigs and
chickens; the concentration is often referred to as
subtherapeutic (not to be confused with sub-
MIC levels). The resulting concentration in the
gastrointestinal tract of the animal is sufficient
to inhibit the susceptible bacteria and markedly
affect the composition of the bacterial gut flora (8).
In Denmark, as well as in other countries,
only a few glycopeptides have been used; for
humans vancomycin and (to a lesser extent)
teicoplanin have been used, and for animals
avoparcin has been used exclusively as a feed
additive for growth promotion. Avoparcin has
not been used in animals in Sweden since 1986
because of a national prohibition of AGPs; in the
United States, avoparcin was never approved
because of its carcinogenic effects (9).
Few countries have accurate data on the use
of antibiotics in animals and humans. In
Denmark, 24 kg of active vancomycin was used
for human therapy in 1994. In comparison,
24,000 kg of active avoparcin was used as a feed
additive for animals (10). In Austria, an average
of 582 kg of vancomycin was imported for
medical purposes and 62,642 kg of avoparcin for
animal husbandry per year from 1992 to 1996
(11). Thus, although there are more food animals
than humans, the selective pressure favoring
VRE in Europe can be estimated to be much
higher in food animals than in humans. Data on
the yearly use of vancomycin in the United
States and in major European countries were
recently published by Kirst et al. (12). Denmark,
a small country, used more glycopeptide growth
promotant (avoparcin) than all of Europe and the
United States used for treating ill humans
(vancomycin). Difference in denominators im-
plies huge difference in use (10).
Use of Avoparcin as a Growth Promoter
and the Occurrence of VRE in Food
Animals
The high selective pressure by the use of
glycopeptides as growth promoters could explain
the presence of VRE in food animals. We have
conducted a number of studies to investigate the
association between the use of avoparcin as a
growth promoter and the occurrence of VRE.
In one study, eight poultry flocks raised
conventionally and six raised without growth
promoters were compared (13). No VRE was
found in birds raised without growth promoters,
whereas five out of eight conventional flocks
contained VRE. Isolation rates in positive flocks
were as follows: of five fecal samples tested, one
to four (20%80%) were positive. Twenty-two pig
herds and 24 poultry flocks, half of which had
used avoparcin and half of which had not, were
compared by occurrence of VRE in fecal samples
collected from animals of the herds and flocks. A
strong and statistically highly significant
association between the presence of VRE and the
use of avoparcin was observed (14). Of 12 pig
herds using feed with avoparcin, 8 had VRE,
while of 10 herds not using avoparcin, 2 had VRE
(p = 0.043, risk ratio [RR] 3.3; 95% confidence
interval [CI]: 1.1, 10.0). In broiler farms where
avoparcin was used, VRE was isolated from 11 of
12 fecal samples. In farms where avoparcin was
not used, VRE was isolated in 2 of 12 samples
(p <0.0006; RR 5.5; 95% CI: 2.2, 13.9).
The association observed at the flock and
herd level has also been observed at the country
level. In countries where avoparcin had been
used as a growth promoter, VRE could
frequently be cultured from food animals,
whereas in countries where avoparcin had not
been used, VRE were not detected (Table 1). These331 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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findings are consistent with the hypothesis that
use of avoparcin has created a reservoir for VRE
in food animals.
Transmission of VRE from Animals to
Humans
Can an animal reservoir in itself be regarded
a public health risk? What are the chances that
VRE or the resistance genes will be transmitted
from animals to humans? A public health risk
must be assumed to exist when transfer from
animals to humans can be shown directly or
indirectly.
VRE are frequently present in food produced
in Denmark as well as in food imported into
Denmark from other European countries (23,24).
Thus, exposure to humans from insufficiently
heated food or cross-contaminated ready-to-eat
food takes place. Unlike studies in the United
States (21,25), European studies reported that
humans frequently are fecal carriers of VRE (26-
29). This suggests that VRE can be ingested from
food in Europe. Furthermore, VRE was not
detected in strict vegetarians in The Nether-
lands, supporting the view that the source of
VRE is contaminated meat (Table 2) (28).
Molecular typing shows a very high diversity
of VRE types in animals as well as humans (30).
Nevertheless, similar or related types have been
shown to occur in animals and humans on a
number of occasions, supporting the assumption
that transfer of VRE between humans and
animals does take place (18,19). We have
recently compared 84 isolates of E. faecium from
swine, chickens, and humans in Denmark by
SmaI generated macrorestriction profiles and
EcoRI ribotyping. Similarity analysis by
unweighted pair group method with arithmetic
averagesderived dendrograms did not indicate
a higher degree of similarity among E. faecium
isolates (VRE as well as non-VRE) from humans
than from animals. This finding indirectly
supports the hypothesis that E. faecium from
different food animals and humans are not
discrete populations but belong to a common pool
of  E. faecium shared by animals and humans
(data not shown).
The  VanA gene cluster encoding for
vancomycin resistance in animal and human
VRE is located on a transposon designated
Tn1546  (31,32). Tn1546 can easily spread from
one enterococcal species to another as well as
from enterococci to S. aureus (33,34). Recent
investigations have documented that in vivo
transfer of Tn1546 can take place in the
mammalian intestinal tract (A. Sundsfjord, pers.
comm.). Furthermore, animal VRE can colonize
the human intestinal tract for at least 3 weeks
after experimental ingestion of 107 CFUs of a
single strain (35). This indicates that vancomy-
cin resistance can spread in the gastrointestinal
tract from transiently colonizing animal VRE to
E. faecium strains of the resident human gut flora.
The  VanA gene cluster consists of several
genes. We investigated the genes and the regions
between them by sequencing of selected areas,
polymerase chain reaction amplification of other
areas, and hybridization with specific probes
(36,37). Thirteen different types were observed.
Most differences arose from the presence of
insertions or deletions in noncoding intergenic
regions. One nucleotide difference was observed
in the coding sequences; this point mutation
occurred in the vanX gene at position 8234,
where a G in the reference VRE strain was
substituted for a T in some isolates.
In human VRE isolates, this mutation was
evenly distributed, whereas in poultry isolates
from different countries only the G variant
Table 1. Avoparcin as a growth promoter in countries
where the occurrence of vancomycin-resistant entero-
cocci (VRE) in animal husbandry has been investigated
 VRE in
Avoparcin   animal
Country     used husbandry   Ref.
Belgium + + 15
Denmark + + 13,14
Finland + + 16
France + + 17
Germany + +   7
Great Britain + +   6
The Netherlands + + 18
Norway + + 19
Sweden - - 20
United States - - 21,22
Table 2. Prevalence of vancomycin-resistant Enterococ-
cus faecium in fecal samples of residents in a vegetarian
and a nonvegetarian nursing home, The Netherlands (28)
No. E.
No. persons faecium No. VRE
investigated positive positivea,b
Vegetarians 42 23 0
Nonvegetarians 62 32 6
aP<0.05.
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occurred; in isolates from swine from different
countries the T variant occurred in nearly all
isolates (Table 3). Although we have no
explanation for the uneven distribution of
subtypes between different animals, the finding
of both types in humans does support the
hypothesis that animals are a primary source of
vancomycin resistance genes in humans,
whereas humans apparently do not serve as
reservoir for animals, in which case both types
would be expected to occur in both animal
species. In the same investigation, we found that
all human isolates from a Muslim country
belonged to the poultry subtype (37). The
absence of pork variant types in a Muslim
country suggests that food of animal origin is a
major reservoir for VRE in humans.
The European/American Paradox
Even though the greater frequency of VRE
infections in U.S. than in European hospitals
would seem to contradict it (12), the hypothesis
that animals could serve as reservoirs of human
VRE infections is supported by several lines of
indirect evidence.
Heavy use of vancomycin (and probably also
third-generation cephalosporins) is a prerequi-
site for frequent VRE infections in hospitals.
Heavy use of vancomycin and third generation
cephalosporins is more frequent in U.S. than in
European hospitals (12,18). Thus, the problem in
Europe, irrespective of a high carrier rate of VRE
in the community, has not grown to the same
proportions as in the United States. VRE
infections in the United States are probably due
to the heavy use of antibiotics in hospitals and
the eventual spread of VRE within and among
hospitals by carrier personnel (38).
Another prerequisite for high incidence of
VRE hospital infections is a source of VRE. In the
United States, primary sources of VRE to
hospitals include travelers returning from
abroad, tourists, and imported food. Once inside
the hospital, VRE can cause nosocomial outbreaks
because of its high potential to colonize and
persist in the environment, which facilitates its
persistence and spread (4). An alternative
hypothesis could be that some clones of VRE
have a higher potential to cause infections and
that such clones are more prevalent in United
States. This hypothesis, however, is contradicted
by the high number of different types of VRE
causing infections in Europe and the United
States, which suggests that pathogenic potential
is not limited to a few clones of VRE (38).
Avoparcin was approved for growth promo-
tion in Europe in 1974. The first VRE was
detected in a human patient in France in 1986.
Does this suggest that VRE was not present in
animals before 1986? Historically, resistance to
growth promoters in animal bacteria was not
monitored, and with few exceptions the studies
conducted have looked at bacteria other than
enterococci because enterococci were not
considered foodborne pathogens. Thus, if VRE
were not detected in food animals, it may be
because they were not looked for.
The Effect of Prohibiting Use of Avoparcin
as a Growth Promoter
Because of public health concerns about
resistance to glycopeptide antibiotic drugs,
avoparcin was banned in Denmark in 1995. In
1996, Germany took a similar step, and finally in
1997, avoparcin was banned in all EU member
states. After the ban in Denmark, a marked
reduction in the occurrence of VRE in Danish
poultry flocks has been observed at slaughter
(from 82% in 1995 to 12% of flocks in 1998;
x2 = 68.3 on 5 df.; p <0.0001), whereas in swine
only a minor reduction has been observed
(Figure) (39). In Germany, a decrease in the
incidence of VRE in poultry meat and in fecal
samples from humans in the community was
observed after discontinuation of avoparcin use
in animal husbandry (40). In poultry meat the
proportion of VRE-positive samples were
reduced from 100% in 1994 to 25% in 1997, and in
fecal samples from humans in the community,
the carrier rate decreased from 12% in 1994 to
3% in 1997.
Table 3. Variations in Tn1546-like elements of
vancomycin-resistant Enterococcus faecium isolates
of animal and human origin (37)
   No.      T      G
Source isolates variant variant
Humans   45 16   29
Pigs   33 32     1
Poultry 193   0 193
Total 271 48 223333 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Similar Problems Related to Other
Antimicrobial Growth Promoters
Most of the different growth promoters
approved in the EU are active against gram-
positive bacteria. With increasing resistance in
gram-positive pathogenic bacteria, antimicrobial
drugs used as growth promoters have attracted
renewed attention as potentially useful for
human therapy. More than 10 years after the
first VRE was discovered, the first drug for
humans with good clinical effect against VRE
infections is ready to be marketed. This drug is a
combination of two streptogramins, quinupristin
and dalfopristin (Synercid).
For decades, virginiamycin, which belongs to
the group of streptogramins, has been used as a
growth promoter in the European Union as well
as in the United States, primarily for poultry
production. Investigations in the United States,
The Netherlands, and Denmark have frequently
found Synercid-resistant E. faecium in poultry
(41-43). As for VRE, we have no data on the
prevalence of streptogramin-resistant E. faecium
in animal husbandry before virginiamycin was
used as a growth promoter. No monitoring has
been carried out. Moreover, the gene (satA)
conferring resistance to virginiamycin and
Synercid have been found in animals and
humans (44), and in vivo transfer of these genes
from resistant to sensitive strains of E. faecium
in the mammalian gastrointestinal tract has
been shown (45). Thus, the events associated with
avoparcin and vancomycin may be recurring for
Synercid and virginiamycin. Furthermore, the
drug anticipated to be next in line after Synercid,
a compound called Ziracin, belonging to the class
of everninomicins, is practically identical to
another growth promoter called avilamycin,
which has primarily been used in poultry.
We have detected avilamycin resistance in
69% of E. faecium isolates from poultry in
Denmark (43). Moreover, preliminary investiga-
tions show that resistance to avilamycin gives
cross-resistance to Ziracin and that a transfer-
able genetic element may be involved (46). Thus,
again use of an antimicrobial drug as a growth
promoter may have created a major animal
reservoir of resistant E. faecium, threatening to
shorten the life span of a new promising drug
when it is put to use in humans.
Future Perspectives
At the core of the VRE issue appears to be the
way antimicrobial drugs are being developed.
New classes of antimicrobial drugs are not
available. Instead, old drugs are being modified
that may have been used in agriculture as
growth promoters for decades because they were
not considered useful for humans. Now that
physicians are searching for more options in
antibiotic treatment, the older drugs may no
longer be viable. The use of antimicrobial drugs
and development of resistance in animals and
humans are interrelated. Therefore, systems to
monitor antimicrobial resistance in pathogenic
and commensal bacteria should be established.
Such systems should cover relevant bacteria
from the entire farm-to-fork chain and monitor
resistance towards antimicrobial drugs used in
both animals and humans, including growth
promoters (47-49).
Finally, antimicrobial agents should not be
used for growth promotion if they are used in
human therapeutics or are known to select for
cross-resistance to antimicrobial drugs used in
human medicine (47). Antimicrobial agents are
too valuable to be used as a tool in animal
production because any antimicrobial drug may
be useful for human therapy in the future even if
not used therapeutically today. Adherence to the
World Health Organization recommendations
(47) will ensure a systematic approach toward
replacing antimicrobial growth promoters with
safer nonantimicrobial drug alternatives. The EU
countries entered this process in December 1998
when four growth promoters (tylosin, spiramycin,
bacitracin, and virginiamycin) were banned
because of their structural relatedness to
Figure. Trend in the proportion of Enterococcus
faecium isolates resistant to vancomycin (VRE)
during successive half-year periods from second half
of 1995 to first half of 1998 (39).334 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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therapeutic antimicrobial drugs used for
humans (50).
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